Rifaximin therapy for patients with irritable bowel syndrome without constipation.

By M. Pimentel, A. Lembo, W. Chey, S. Zakko, Y. Ringel, Jing Yu, S. Mareya, Audrey L. Shaw, E. Bortey, W. Forbes. New England Journal of Medicine, 2011

957 citations recorded by the source corpus.

Subfields: Gastroenterology, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/4130f5b4313b31c38613f745d033c0119b7f4051

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Gastroenterology

1. J. Cryan
2. J. Foster
3. L. Rinaman
4. M. Simrén
5. James Versalovic
6. B. Lacy
7. F. Bäckhed
8. E. Quigley

In Molecular Biology

1. J. Cryan
2. B. B. Finlay
3. J. Foster
4. L. Rinaman
5. E. Quigley
6. P. O’Toole
7. James Versalovic
8. Vincent B. Young

In Surgery

1. J. Cryan
2. B. B. Finlay
3. F. Bäckhed
4. J. Cawley
5. Chad D Meyerhoefer

Citations in the corpus

• The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems (2015, background): “Microbiota may interplay with multiple of these different pathophysiological IBS targets [14] and its role is supported by varying lines of evidence: the presence in IBS patients of alterations in microbiota composition with defects both in its stability and diversity, the development of post-infect”
• An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota (2011, background): “This and the hypothesis that small intestinal bacterial overgrowth might also contribute to IBS symptomatology(5) have motivated investigation of antibiotics as therapeutic agents in IBS.(6) Large double-blind studies of some antibiotics have shown an improvement (albeit modest, though statistically”
• Intestinal microbiota in functional bowel disorders: a Rome foundation report (2012, background): “Moreover, it is likely that patients may require repeated courses of therapy, as trial evidence suggests the benefit diminishes by 12 weeks.(189) The best evidence is for rifaximin 550 mg, thrice daily for 2 weeks.”
• Bowel Disorders. (2016, background): “BO W EL 550 mg 3 times daily in patients with nonconstipated IBS resulted in significantly more patients reporting adequate relief of global IBS symptoms and bloating during the first 4 weeks of follow-up.(58) Improvement in symptoms relative to placebo persisted for the 10-week follow-up period, ev”
• Mechanisms and consequences of intestinal dysbiosis (2017, background): “Such an eubiotic effect is typical for rifaximin, which contributes to increasing the gut microbial diversity in IBD patients [94] and also improves symptoms of irritable bowel syndrome [95].”
• ACG Clinical Guideline: Management of Irritable Bowel Syndrome. (2020, background): “001) when both trial results were pooled in the follow-up month (200).”
• Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. (2012, background): “…data have shown that they can also be beneficial in certain disease conditions that do not have established pathogen-associated etiology such as IBD and irritable bowel syndrome (IBS), although the precise mechanism of effect is not completely understood (Khan et al., 2011; Pimentel et al., 2011).”
• Stress & the gut-brain axis: Regulation by the microbiome (2017, positive): “Many of the preclinical models of increased visceral pain are induced by applying a psychological or physical stressor that relate to factors known to predispose to IBS, a clinical disorder characterized by visceral hypersensitivity to pain (Mayer et al., 2001).”
• CLINICAL PRACTICE GUIDELINES FOR THE PERIOPERATIVE NUTRITIONAL, METABOLIC, AND NONSURGICAL SUPPORT OF THE BARIATRIC SURGERY PATIENT—2013 UPDATE: COSPONSORED BY AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, THE OBESITY SOCIETY, AND AMERICAN SOCIETY FOR METABOLIC & BARIATRIC SURGERY (2013, background): “[388] Pimentel M, Lembo A, Chey WD, et al.”